Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Targeting of tumor antigen CD38 and stress antigens MICA/B by CAR T cells provides a unique approach for the comprehensive treatment of multiple myeloma

Blood (2025) 146 (Supplement 1): 2350.

https://doi.org/10.1182/blood-2025-2350

Published: 2025

Journal Articles

CLL-1 chimeric antigen receptor T-cells for the treatment of Acute Myeloid Leukemia: A phase 1 clinical trial

Erin Doherty, LaQuisa Hill, Daniil Shmidt, Mengfen Wu, Tao Wang, Bambi Grilley, George Carrum, Premal Lulla, Carlos Ramos, John Craddock, Bahey Salem, Gabriela Llaurador Caraballo, Robert Krance, Caridad Martinez, Helen Heslop, Malcolm Brenner, Maksim Mamonkin

Blood (2025) 146 (Supplement 1): 2372.

https://doi.org/10.1182/blood-2025-2372

Published: 2025

Journal Articles

Development of next generation multi-antigen targeting off-the-shelf CAR T cells for conditioning-free treatment of B-cell lymphoma

Shilpi Chandra, John Reiser, Brian Groff, Carissa Dege, Bryan Hancock, Alison O'Connor, Alma Gutierrez, Angela Gentile, Tom Lee, Ramzey Abujarour, Raedun Clarke, Betsy Rezner, John Goulding, Jode Goodridge, Karl-Johan Malmberg, Maksim Mamonkin, Bahram Valamehr, Alex Garcia, Martin Hosking

Blood (2025) 146 (Supplement 1): 4121.

https://doi.org/10.1182/blood-2025-4121

Published: 2025

Journal Articles

The development of FT839: An off-the-shelf CD19xCD38 dual-CAR T cell for the treatment of multiple myeloma

Blood (2025) 146 (Supplement 1): 7631.

https://doi.org/10.1182/blood-2025-7631

Published: 2025

Journal Articles

Interim analysis of safety and efficacy in a Phase 2 study of MB-105, a CD5.CAR T therapy for patients with relapsed/refractory T cell lymphoma

Blood (2025) 146 (Supplement 1): 775.

https://doi.org/10.1182/blood-2025-775

Published: 2025

Journal Articles

The development of an off-the-shelf CAR T-cell therapy co-targeting CD19 and CD38 for broad application in autoimmune disease

Blood (2025) 146 (Supplement 1): 5895.

https://doi.org/10.1182/blood-2025-5895

Published: 2025

Journal Articles

CART-007: a license to kill

Swati Naik, Maksim Mamonkin

Blood (2025) 146 (10): 1145–1146.

https://doi.org/10.1182/blood.2025029626

Published: 2025

Journal Articles

CD7 CAR-T: a bridge to transplant in AML

Maksim Mamonkin

Blood (2025) 145 (10): 995–996.

https://doi.org/10.1182/blood.2024027442

Published: 2025

Journal Articles

Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 Is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy

Alan Williams, Rina Mbofung, Daniel Morales-Mantilla, Brian Groff, Alison O'Connor, Binzhong Li, Ramesh Janani, Betsy Rezner, Mark Jelcic, Yijia Pan, Tom Lee, Karl-Johan Malmberg, Maksim Mamonkin, John Goulding, Jode Goodridge, Bahram Valamehr

Blood (2024) 144 (Supplement 1): 503.

https://doi.org/10.1182/blood-2024-210846

Published: 2024

Journal Articles

Confirmatory Efficacy and Safety Evaluation of MB-105, a CD5.CAR T Therapy: Multicenter Phase 2 Study in Patients with Relapsed/Refractory T Cell Lymphoma (R/R TCL)

Swaminathan P Iyer, LaQuisa Hill, Steven Horwitz, Salvia Jain, Christina Poh, Julie M. Vose, Malcolm K. Brenner, Maksim Mamonkin, Sarah Hein, Federica Giordano, Alice Bexon

Blood (2024) 144 (Supplement 1): 7223.

https://doi.org/10.1182/blood-2024-201523

Published: 2024

Journal Articles

Targeting IDH2 R140Q and other neoantigens in acute myeloid leukemia

Wingchi K. Leung, Alejandro G. Torres Chavez, Matthew French-Kim, Paul Shafer, Maksim Mamonkin, LaQuisa C. Hill, Manik Kuvalekar, Yovana Velazquez, Ayumi Watanabe, Norihiro Watanabe, Valentina Hoyos, Premal Lulla, Ann M. Leen

Blood (2024) 143 (17): 1726–1737.

https://doi.org/10.1182/blood.2023021979

Published: 2024

Includes: Supplemental data

Journal Articles

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas

Blood (2024) 143 (13): 1231–1241.

https://doi.org/10.1182/blood.2023022204

Published: 2024

Includes: Supplemental data

Journal Articles

Combining Apoptotic Resistance and Cytokine Signaling to Improve Persistence and Anti-Tumor Activity of CAR Vδ2 T Cells In Vivo

Leonard Leong, Mansi Narula, Helen Elisabeth Heslop, Malcolm K. Brenner, Maksim Mamonkin, Norihiro Watanabe

Blood (2023) 142 (Supplement 1): 3440.

https://doi.org/10.1182/blood-2023-187658

Published: 2023

Journal Articles

Allogeneic Veto-CAR CD8 T Cells Enabling Prolonged Graft Survival, Anti-Tumor Specificity, and Low Risk of Graft Versus Host Disease

Wei-Hsin Liu, Anat Globerson Levin, Assaf Lask, Galit Horn, Tova Waks, Bar Nathansohn Levy, Maksim Mamonkin, Zelig Eshhar, Richard E. Champlin, Yair Reisner, Esther Bachar Lustig

Blood (2023) 142 (Supplement 1): 4833.

https://doi.org/10.1182/blood-2023-175033

Published: 2023

Journal Articles

Splendid isolation

Dimitrios Laurin Wagner, Maksim Mamonkin

Blood (2023) 141 (22): 2665–2666.

https://doi.org/10.1182/blood.2023019864

Published: 2023

Journal Articles

Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation

Feiyan Mo, Norihiro Watanabe, Kayleigh I. Omdahl, Phillip M. Burkhardt, Xiaoyun Ding, Eiko Hayase, Angela Panoskaltsis-Mortari, Robert R. Jenq, Helen E. Heslop, Leslie S. Kean, Malcolm K. Brenner, Victor Tkachev, Maksim Mamonkin

Blood (2023) 141 (10): 1194–1208.

https://doi.org/10.1182/blood.2022016052

Published: 2023

Includes: Supplemental data

Journal Articles

Engineering naturally occurring CD7 − T cells for the immunotherapy of hematological malignancies

Blood (2022) 140 (25): 2684–2696.

https://doi.org/10.1182/blood.2021015020

Published: 2022

Includes: Supplemental data

Journal Articles

Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following CAR-T Therapy

Jay A. Read, Feiyan Mo, Maksim Mamonkin, Rayne H. Rouce, Katherine Y. King

Blood (2022) 140 (Supplement 1): 10271–10272.

https://doi.org/10.1182/blood-2022-159579

Published: 2022

Journal Articles

Alloimmune Defense Receptor Harnesses Host Immune Cell Activation to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf, Cell-Based Cancer Therapy

Alan M Williams, Ken L Hayama, Yijia Pan, Brian Groff, Rina M Mbofung, Amber Chang, Christine Chen, Lauren Fong, Nicholas Brookhouser, Berhan Mandefro, Ramzey Abujarour, Tom Lee, Maksim Mamonkin, Raedun Clarke, Ryan Bjordahl, Jode P Goodridge, Bahram Valamehr

Blood (2022) 140 (Supplement 1): 4547–4548.

https://doi.org/10.1182/blood-2022-167139

Published: 2022

Journal Articles

CD7 CAR: sword and shield

M. Paulina Velasquez, Maksim Mamonkin

Blood (2022) 140 (4): 293–294.

https://doi.org/10.1182/blood.2022016595

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Targeting of tumor antigen CD38 and stress antigens MICA/B by CAR T cells provides a unique approach for the comprehensive treatment of multiple myeloma

CLL-1 chimeric antigen receptor T-cells for the treatment of Acute Myeloid Leukemia: A phase 1 clinical trial

Development of next generation multi-antigen targeting off-the-shelf CAR T cells for conditioning-free treatment of B-cell lymphoma

The development of FT839: An off-the-shelf CD19xCD38 dual-CAR T cell for the treatment of multiple myeloma

Interim analysis of safety and efficacy in a Phase 2 study of MB-105, a CD5.CAR T therapy for patients with relapsed/refractory T cell lymphoma

The development of an off-the-shelf CAR T-cell therapy co-targeting CD19 and CD38 for broad application in autoimmune disease

CART-007: a license to kill

CD7 CAR-T: a bridge to transplant in AML

Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 Is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy

Confirmatory Efficacy and Safety Evaluation of MB-105, a CD5.CAR T Therapy: Multicenter Phase 2 Study in Patients with Relapsed/Refractory T Cell Lymphoma (R/R TCL)

Targeting IDH2 R140Q and other neoantigens in acute myeloid leukemia

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas

Combining Apoptotic Resistance and Cytokine Signaling to Improve Persistence and Anti-Tumor Activity of CAR Vδ2 T Cells In Vivo

Allogeneic Veto-CAR CD8 T Cells Enabling Prolonged Graft Survival, Anti-Tumor Specificity, and Low Risk of Graft Versus Host Disease

Splendid isolation

Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation

Engineering naturally occurring CD7 − T cells for the immunotherapy of hematological malignancies

Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following CAR-T Therapy

Alloimmune Defense Receptor Harnesses Host Immune Cell Activation to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf, Cell-Based Cancer Therapy

CD7 CAR: sword and shield

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only